Safety of Thrombolytic Therapy with Urokinase or Recombinant Tissue Plasminogen Activator for Peripheral Arterial Occlusion:A Comprehensive Compilation of Published Work

Abstract

These results from a large body of published literature suggest that urokinase may be associated with a lower incidence of complications than rtPA in the treatment of peripheral arterial occlusions.

Comparative Safety and Efficacy of Urokinase and Recombinant Tissue Plasminogen Activator for Peripheral Arterial Occlusion: A Meta‐Analysis

“…28 A comprehensive review revealed similar rates of major hemorrhage whether patients in clinical trials received rt-PA at dosages of more than or less than 3.5 mg/hr (0.05 mg/kg/hr). 29 The Society of Cardiovascular and Interventional Radiology recommends use of low doses of rt-PA (e.g., 0.12-2.0 mg/hr). 30,31 The dose of urokinase has varied less in the past decade than at other times.…”

Therapeutics targeting the fibrinolytic system

“…R-tPA is used for the treatment of severe thrombotic diseases (e.g., acute ischemic stroke) under extremely strict administration criteria, as the administration of r-tPA confers a high risk of mass hemorrhage 153 . Several types of r-tPA have been commercially available, including Alteplase, Retaplase, or Tenecteplase, but only one uPA product is clinically used for deep venous thrombosis or pulmonary embolism 154 .…”

Frostbite: Spectrum of Imaging Findings and Guidelines for Management

“…Early thrombolytic therapy can reverse the microvascular thrombosis induced by frostbite injuries, thereby reestablishing distal perfusion and limiting tissue loss (3,23). Although the use of intra-arterial thrombolysis for treatment of frostbite injuries is relatively new, early investigations into its benefits have thus far been promising (3,(24)(25)(26)(27)(28).…”